TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Expression of protein biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active prescriptions of proton pump inhibitors dose
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acceptability of anaesthetic methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total amount of BIBR 953 ZW excreted into urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCss of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Safety and tolerability of NM002
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with HIV RNA below LDL and HBV DNA below 2.3log10 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of LVOT pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete aneurysm exclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of contrast extravasation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cessation of haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infant Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Danirixin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Preferred side of the caesarean section scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Identification rate of premalignant and malignant cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: ihMTR ratio at 1.5TMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic transfert (MT) at 1.5TMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myelin water fraction at 1.5TMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity in daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: METS in ergometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No Device related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: No curve progression ˃10° above or below the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Best Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Operative Assessment of Laparoscopic Skill (GOALS)-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infant Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Mean Symptom Complex Severity (MSCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-bearing on the prosthetic side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Onset Diabetes After Renal Transplantation (NODAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percentage Change in Total Surface Area of Oral Ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stanford Self-Management Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activities of Daily Living Rating Scale III
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lipoprotein lipase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-related adverse events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the drug-concentration vs. time curve of nifurtimox
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of nifurtimox characterized by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of nifurtimox characterized by tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with solicited local reaction after any vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with solicited systemic reaction after any vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with Neutrophils results below and above the normal ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serious adverse drug reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severe adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant non-serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Uric Acid Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Switching to standard of care external drain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of bacteraemia-free catheter survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: LV function assessed by 2D echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise tolerance measured with ECG treadmill stress testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: angina severity according to CCS classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Clinically Significant Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Continuous Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cavernosal Artery Mean PSV Before Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cavernosal Artery Mean PSV After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Estimating GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Femorotibial mechanical axis analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in composite cardiovascular disease risk score (z-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Compliant Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Overall Xerostomia Burden at 9 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of recognized epitopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total magnitude of gene-specific CD4 and CD8 T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in end systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of ApoB/ApoA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Percentage of Participants Achieving at Least a 50% Relative Reduction in SALT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Immunogenic Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Short-term Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long-term Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DHE pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Musculoskeletal Function Assessment (SMFA) Overall Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Veterans RAND 12 Item Health Survey - Physical Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Veterans RAND 12 Item Health Survey (VR-12) - Mental Health Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Rathus Assertiveness Schedule
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in test Diagnosis of situational and personal anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Three month clinical score estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six month clinical score estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of neuromotor outcome using sensor and video data from 3 month time-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of neuromotor outcome using sensor and video data from 6 month time-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cognitive Map Formation Test (CMFT) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Route Learning Navigation Test Battery performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Memory Image Completion Task (MIC) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: perceived symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: survivorship of a multihole revision acetabular cup
Endpoint domain: Mortality/survival
Primary endpoint: Attendance at the first early psychosis intervention consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Altered states of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete healing of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSSI frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSSI severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuity in Readings of Contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Continuity in Readings of Fetal Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 90-90 Knee Extension Angle Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rates of influenza infection
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive value of NOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in interoception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of illness and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Health Care Expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skeletal muscle blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diabetes Mellitus (type 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gestational Diabetes Mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypertensive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in morphology of scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Feasibility of study recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of retention of participants at 3-month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of retention of participants at 6-month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the three interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: All grade IVH incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a TEAE of Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Kinematic recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease relevant rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of IL-2 and Treg cell levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in leg pain of 20 mm on a VAS pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of ≥ .5 on ZCQ for both Symptom Severity and Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No major device-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of invasive fungal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Strongest antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in levels of BHCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants in Clinical Remission at 10 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Clinical Remission at 52 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in exhaled carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in blood oxygenation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of single-sampling strategy for early diagnosis of NSTE-ACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall outcomes in patients with cerebral small vessel disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of translational shifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amounts of Radioactivity Excreted in Urine and Faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of Total Radioactivity in Plasma and Whole Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of OPS-2071 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the CGI-21 Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Photoactive Porphyrins Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penetration-Aspiration scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurobehavioral Assessment of the Preterm Infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Pain Visual Analog Scale (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QUALIN score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Success rate in obtaining the Genomic Grade Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Karonudib (TH1579)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of Karonudib (TH1579)
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-specific patient care indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of device-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Likelihood of being concussed
Endpoint domain: Adverse events/effects
Primary endpoint: Blood culture positive incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in prostate cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hearing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on depression and anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardio-vascular toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total area under the plasma drug concentration-time curve from time zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of the analyte in plasma (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional synthetic rates of skeletal muscle proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: degradation of skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Classification performance of appendicitis scoring systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall Frequency Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With a 4 and More Point Increase of the Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treated ventricular tachycardia (VT) events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treated ventricular fibrillation (VF) events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete wound closure by Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse experiences (AEs) related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: First Occurrence of Myocardial Infarction, Acute Coronary Syndrome, Stroke, Heart Failure, or CVD Death
Endpoint domain: Mortality/survival
Primary endpoint: MES COUNT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in International Prostate Symptom Score (IPSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival With no or Mild Neuropsychological Impairment
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with solicited local and systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of vaccine-related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer (GMT) of hemagglutination inhibition assay (HAI) antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower esophageal impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in number of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar spine and femoral neck bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes